Efalizumab
Based on 1 publication(s) in Google Scholar
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.00%
- CAS No.: 214745-43-4
- Masse moléculaire:146.238 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Efalizumab
More
Activité biologique
Human IgG1 kappa
Human
CD11a/LFA-1α
Efalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood[3].
Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 214745-43-4
-
Appearance Liquid
-
Masse moléculaire 146.238 kDa
-
Color Colorless to light yellow
-
SMILES
[Efalizumab]
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S98-104. [Content Brief]
[2]. Berger JR, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009 Nov-Dec;1(6):583-9. [Content Brief]
[3]. Koszik F, et al. Efalizumab modulates T cell function both in vivo and in vitro. J Dermatol Sci. 2010 Dec;60(3):159-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Efalizumab Related Classifications
HY-P9947 Related Classifications
Powered by Bioz